Literature DB >> 7569514

An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation.

J Wakefield1, A Racine-Poon.   

Abstract

Population pharmacokinetic data consists of dose histories, individual covariates and measured drug concentrations with associated sampling times. Population pharmacodynamic data consist of dose histories, covariates and some response measure. Population analyses, whether they be pharmacokinetic or pharmacodynamic attempt to explain the variability observed in the recorded measurements and are increasingly being seen as an important aid in drug development. In this paper a general Bayesian population pharmacokinetic/pharmacodynamic model is described and an analysis of data for the drug recombinant hirudin is presented. The model we use allows for both outliers and censoring in the concentration data and outlying individual pharmacokinetic parameters. We attempt to address directly important questions such as recommended dose size using predictive distributions for response.

Mesh:

Substances:

Year:  1995        PMID: 7569514     DOI: 10.1002/sim.4780140917

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  11 in total

1.  Likelihood based approaches to handling data below the quantification limit using NONMEM VI.

Authors:  Jae Eun Ahn; Mats O Karlsson; Adrian Dunne; Thomas M Ludden
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-08-07       Impact factor: 2.745

2.  Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method.

Authors:  F Mesnil; F Mentré; C Dubruc; J P Thénot; A Mallet
Journal:  J Pharmacokinet Biopharm       Date:  1998-04

3.  A use of Monte Carlo integration for population pharmacokinetics with multivariate population distribution.

Authors:  A Yafune; M Takebe; H Ogata
Journal:  J Pharmacokinet Biopharm       Date:  1998-02

4.  A comparison of a Bayesian population method with two methods as implemented in commercially available software.

Authors:  J E Bennett; J C Wakefield
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

5.  Modeling of trough plasma bismuth concentrations.

Authors:  J E Bennett; J C Wakefield; L F Lacey
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

6.  A Bayesian hierarchical nonlinear mixture model in the presence of artifactual outliers in a population pharmacokinetic study.

Authors:  Leena Choi; Brian S Caffo; Utkarsh Kohli; Pratik Pandharipande; Daniel Kurnik; E Wesley Ely; C Michael Stein
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-08-17       Impact factor: 2.745

7.  The pharmacokinetics of saquinavir: a Markov chain Monte Carlo population analysis.

Authors:  D J Lunn; L Aarons
Journal:  J Pharmacokinet Biopharm       Date:  1998-02

8.  Weighted target interval stochastic control methods with global optimization and their applications in individualizing therapy.

Authors:  Shaolin Ji; Yingzhi Zeng; Ping Wu; Edmund Jon Deoon Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-05-12       Impact factor: 2.410

9.  Development of a clinical decision model for thyroid nodules.

Authors:  Alexander Stojadinovic; George E Peoples; Steven K Libutti; Leonard R Henry; John Eberhardt; Robin S Howard; David Gur; Eric A Elster; Aviram Nissan
Journal:  BMC Surg       Date:  2009-08-10       Impact factor: 2.102

10.  A molecular computational model improves the preoperative diagnosis of thyroid nodules.

Authors:  Sara Tomei; Ivo Marchetti; Katia Zavaglia; Francesca Lessi; Alessandro Apollo; Paolo Aretini; Giancarlo Di Coscio; Generoso Bevilacqua; Chiara Mazzanti
Journal:  BMC Cancer       Date:  2012-09-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.